Does Garlic Supplementation Control Blood Pressure in Patients with Severe Coronary Artery Disease? A Clinical Trial Study
نویسندگان
1 Cardiovascular Intervention Research Center, Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
2 Department of Guilan Interventional Cardiovascular Research Center, Heshmat Hospital, Guilan University of Medical Sciences, Rasht, IR Iran
3 Department of Guilan Interventional Cardiovascular Research Center, Heshmat Hospital, Guilan University of Medical Sciences, Rasht, IR Iran
4 Radiology Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran
doi
چکیده
Hypertension is one of the major risk factors for cardiovascular morbidities, including coronary artery disease (CAD).Objectives: With interest on the important role of hypertension in the progression of CAD, this study was designed to estimate theeffect of garlic powder tablets on the blood pressure (BP) in patients with severe CAD.Methods: A randomized, placebo-controlled, clinical trial was conducted on 56 CAD patients, aged 25 - 75 years old. The patientswere randomly divided into two groups: Galois groups (n = 27), receiving garlic powder tablet (400 mg garlic) twice daily and theplacebo groups (n = 29), receiving placebo for 3 months. The BP was assessed at baseline and at the end of the study.Results: During the 3monthsstudy, in the placebo group, systolic BP (SBP) increased with6.3mmHganddiastolic BP (DBP) increasedwith 4.6mmHg,changes which were significant. After the 3 months, the effect of garlic on SBP, after adjusting for baseline value, wassignificant, and this effect wasmoresignificant in hypertensive patients. Plasma lipids and lipoproteins did not change significantlyin either the garlic or placebo groups, during the study. Tolerability, compliance and acceptability were high in all patients.Conclusions: These results demonstrate that treatment with garlic-based drugs can be an effective treatment for controlling BPin CAD patients and has no interaction with other drugs that CAD patients take. Therefore, it may be considered as a safe adjuncttreatment for this group of patients.